Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Mid-October 2026 announcements show AI moving into three layers at once. Local and edge compute is one: NVIDIA RTX Spark laptops, ASUS, Adobe, Microsoft's hybrid-intelligence Windows, Harvest Praxis with MediaTek, and Hesai's Kosmo world-data engine. Enterprise agent governance is another: ServiceNow's AI Passport and Control Tower, Parloa with TELUS Digital, and Intuit's international rollout. The third is AI-infrastructure scale-up, such as Cisco and NVIDIA's open 400G optics. Salesforce's deal to acquire Braze and SKYX's financed Deako merger point to consolidation in customer-engagement and smart-building software. Executives frame physical-AI data as the main bottleneck, and the Encord co-CEO's call for investment in it reflects wide optimism about funding and applications.
Q3 2026 CFO commentary shows a split economy. Lam Research's CFO describes AI-driven wafer fab equipment demand running ahead of supply-chain capacity, with 2027 expected to be higher. Dow and Union Pacific, by contrast, are protecting earnings through cost cuts, restructuring, price increases and balance-sheet management against high energy and fuel costs. Smaller items add regulatory and leadership-change pressure: the Durbin Amendment's effect on Origin Bancorp, a pending FDA decision on ivonescimab, CFO turnover at Rivian and Union Pacific, and early signs of agentic AI adoption in corporate finance.
Oncology news in October 2026 clusters around the ESMO Congress. Regulators issued a run of positive opinions and approvals (CHMP on RASONQUE and Libtayo, FDA on Tecentriq, AstraZeneca's ZEGFROVY launch). Summit's ivonescimab gained ground with positive Phase III HARMONi-GI1 overall survival data and a new ECOG-ACRIN Phase II/III study. In the background, AstraZeneca is pitching AI-and-robotics 'lab of the future' biologics discovery, and small-cap names such as Spago (delisting) and Akari (ADC-refractory niche) show how uneven the capital picture is below the large caps.
Mid-October 2026 saw a sharp risk-off move in AI-linked assets: the SOX fell eight straight days (longest streak since 2008), the Nasdaq 100 had its worst week since April 2025, and CoreWeave dropped 25% on the week as its default protection hit a record. The selloff reflects worries over credit risk in debt-financed data center buildouts, even as AI keeps spreading into healthcare, defense, retail, education and consumer products. SpaceX's Q3 beat and the possible SpaceX-Tesla merger (with shared superintelligence software work) offer a countervailing bullish signal. Alphabet's bull case names unprecedented AI capex and legal and regulatory pressure as its main risks. The Joonko fraud guilty plea is a reminder of AI-washing and governance risk.
Lam Research reported record September-quarter results. It raised its 2026 wafer fab equipment (WFE) forecast to the mid-$150B range and gave a preliminary 2027 outlook above $200B. It also raised its cumulative Aether revenue target to about $2.5B by decade-end. Growth is led by DRAM, leading-edge foundry and advanced packaging as AI workloads raise etch and deposition intensity. Supply constraints in clean room space and components are expected to cap near-term output. Alongside this, a cluster of CEO appointments (Ipsos, Telenet, Groupe SEB) and small AI and regulatory-tech founders (Numeracle, FSH Technologies) reflect a broader leadership turnover and a pragmatic, tool-based approach to AI. These are loosely connected to the core story.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedNuScale Powers Up 11%, Oklo Climbs 6%, Nano Nuclear Rises 5% as the Nuclear Sector Posts Back-to-Back Rallies
“NuScale Powers Up 11%, Oklo Climbs 6%, Nano Nuclear Rises 5% as the Nuclear Sector Posts Back-to-Back Rallies Quick Read NuScale Power (SMR) stock surged today, extending a two-day rally sparked by White House space nuclear mandate…”
Fortinet Delivers Isolated Infrastructure Acceleration for the AI Factory with NVIDIA
“Fortinet Delivers Isolated Infrastructure Acceleration for the AI Factory with NVIDIA Fortinet, Inc. Collaboration integrates firewalling, segmentation, and policy enforcement directly into NVIDIA BlueField-accelerated infrastructure for higher performance, stronger isolation, and simpler operations SUNNYVALE, Calif…”
14 repeat founders building agentic commerce
“CB Insights - Enterprise Ai Title: 14 repeat founders building agentic commerce Date: 2026-10-23 15:12 Source: https://www.cbinsights.com/research/14-repeat-founders-building-agentic-commerce/ <p><span style="font-weight: 400;">Some of the founders who helped build online shopping are now preparing for AI agents to do…”
Stocks Climb on US-Iran Peace Talk Optimism and a Favorable PPI Report
“Stocks Climb on US-Iran Peace Talk Optimism and a Favorable PPI Report The S&P 500 Index ($SPX) (SPY) today is up +0.39%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.76%…”
Corporate America’s big job cuts in 2026 - What do we know so far?
“Corporate America’s big job cuts in 2026 - What do we know so far? Corporate workers in America have faced the brunt of job cuts since the start of the year…”
Liberty Global outlines Ziggo Group spin-off and targets $1.5B corporate cash by 2026 amid major UK/Netherlands transactions
“Liberty Global outlines Ziggo Group spin-off and targets $1.5B corporate cash by 2026 amid major UK/Netherlands transactions Earnings Call Insights: Liberty Global (LBTYA) Q4 2025 MANAGEMENT VIEW * Michael Fries, Vice Chairman, President, CEO & Chairman of the Board, highlighted two major new transactions: the acquisit…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Third-quarter calls from Lam Research, Dow and Union Pacific show two economies. AI-linked chip demand is outrunning supply, while chemicals and rail protect profit through cost cuts. Every figure is traced to a named speaker, an SEC filing or a source document.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
The FDA approved a twelfth Tecentriq use, and a decision on Summit's ivonescimab is due Nov 14. Summit's SEC-filed accounts show losses and cash burn rising sharply. AstraZeneca's AI vision is, by its own telling, a forecast and not yet a result.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
Cancer drug makers are betting on newer treatment types, and regulators have started to approve some. Summit Therapeutics' filings show how costly that bet is: a $1.08 billion net loss in 2025 with zero revenue. The FDA rules on its lead drug on Nov. 14. The AI claims behind the story are forecasts, not results.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Verified SEC figures show Nvidia's cost of revenue rose about 3.8 times in two fiscal years. A survey says every respondent plans to use AI agents, but company data and trust lag. That survey's source failed our check on all 11 claims we tested, so we flag it and lean on the data that held.
SEC-filed figures show Micron nearly doubled its capital spending in fiscal 2025 and now holds about 2.5 times the cash it had a year earlier. Analyst enthusiasm for power, data-center and quantum stocks rests on sources that held up only about half the time in our checks.
Companies from Manulife to Box customers are rolling out AI agents, and funding is flowing. But a trade-press study reports that in 'data laggard' firms, AI can reach 30% or less of company data. That source has a poor measured record, so we flag it as a claim, not a fact.
Every company surveyed by MIT Technology Review plans to use AI agents within two years, yet firms with weak data give those agents access to 30% or less of it. Only some of this is firmly established: that survey's source scores 0% on our reliability check, and the Nvidia figures are SEC-verified.
Adobe's weak guidance, Alphabet's negative free cash flow, and a wave of safety-driven departures from Anthropic, Google and OpenAI show investors and insiders both demanding proof, not promises — even as California moves first to regulate AI's reach into children's lives.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.